Cytodyn Inc
OTC:CYDY
Cytodyn Inc
Depreciation & Amortization
Cytodyn Inc
Depreciation & Amortization Peer Comparison
Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors
Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cytodyn Inc
OTC:CYDY
|
Depreciation & Amortization
$40k
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-21%
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
37%
|
CAGR 10-Years
26%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
$4.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$196m
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
14%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$435.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
See Also
What is Cytodyn Inc's Depreciation & Amortization?
Depreciation & Amortization
40k
USD
Based on the financial report for Nov 30, 2023, Cytodyn Inc's Depreciation & Amortization amounts to 40k USD.
What is Cytodyn Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-21%
Over the last year, the Depreciation & Amortization growth was -90%. The average annual Depreciation & Amortization growth rates for Cytodyn Inc have been -66% over the past three years , -38% over the past five years , and -21% over the past ten years .